| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 topline data readout example | GlyphAlloTM (SPT-300, Glyph Allopregnanolone) simulated driving performance in healthy volunteers | Phase 1 | — | Peptides | Psychiatric Disorders | ||
Phase 1 topline data readout example | GlyphAlloTM (SPT-300, Glyph Allopregnanolone) simulated driving performance in healthy volunteers | Phase 1 | — | Peptides | Psychiatric Disorders | ||
Phase 1 topline data readout example | GlyphAlloTM (SPT-300, Glyph Allopregnanolone) simulated driving performance in healthy volunteers | Phase 1 | — | Peptides | Psychiatric Disorders |
Recent Updates
Recently added Catalysts
Seaport Therapeutics, Inc.$21.4
+2.04 (+10.54%)
F 18Pipeline Score Richly Valued Pharma · Clinical
Market Cap
925.28 M
EPS
-
P/E Ratio
-
Value Trade
1.57 M
4.35 %
Week
-8.71 %
1 Month
-8.71 %
3 Month
-8.71 %
6 Month
-8.71 %
5 Year
-8.71 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
194.41 K
52 Week Range
14.85 - 19.17
% held by Insiders
67.27 %
% held by Institutions
5.22 %
Enterprise Value
1.04 B
Total Shares
52.87 M
Short %
11.07 %
Float Shares
16.97 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F18
Pipeline Score $41M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.0x
rNPV / MCap Top 17%
Micro Cap (rank 752 of 905)
Percentile RankSeaport Therapeutics, Inc. has significant pipeline risk (18/100), with $137M risk-adjusted pipeline value, led by SPT-300 in Major Depressive Disorder (MDD) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SPT-300 Small molecule | Major Depressive Disorder (MDD) | Phase 2 | NCT07161700 | 12% | $137M | ENROLLING BY_INVITATION | 720 | FAST | D (26) | May 1, 2027 | - | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SPTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SPTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SPTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SPTX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SPTX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SPTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SPTXPureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics, a company founded by PureTech, has announced positive results from its Phase 1 proof-of-concept trial of GlyphAgo™. The trial involved healthy volunteers and demonstrated encouraging data regarding the drug's safety and efficacy. These findings suggest potential for further development in the therapeutic landscape.
Read more →SPTXSeaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics reported its Q1 2026 financial results, highlighting advancements in its clinical programs for neuropsychiatric disorders. The company is actively enrolling patients in the Phase 2b BUOY-1 trial for GlyphAllo, with topline data expected in early 2027. Additionally, new data from the GlyphAgo program indicate promising safety and efficacy profiles. The recent IPO raised $260 million to support ongoing development.
Read more →SPTXSeaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics has announced positive results from a Phase 1 proof-of-concept trial for GlyphAgo™, demonstrating its safety and tolerability in healthy volunteers. The multiple-ascending dose data supports further development of the therapy. This marks a significant milestone for the company in advancing GlyphAgo™.
Read more →SPTXSeaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Seaport Therapeutics has announced the pricing of its upsized initial public offering, offering 14,160,000 shares at $18.00 each, totaling approximately $254.9 million. The shares are set to begin trading on the Nasdaq Global Select Market on May 1, 2026. The offering is expected to close on May 4, 2026, pending customary conditions.
Read more →Competitive Position
How SPTX ranks across every disease it competes inCompetitive Position is a premium feature
See how SPTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial